DNA, Gene Sequencing and Immune Response - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

DNA

Gene Sequencing

Immune Response

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

FEBRUARY 23, 2022

Interest in non-viral methods of delivering gene therapies has been growing in the face of current scrutiny of the safety of viral vectors like adeno-associated viruses (AAV), with a number of clinical programmes based on AAV under clinical holds imposed by the FDA.

Gene Therapy

Gene Therapy Gene Gene Sequencing Immune Response

Zynteglo halt re-ignites viral vector safety concerns; analysts

pharmaphorum

FEBRUARY 22, 2021

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche’s Luxturna and Novartis’ Zolgensma. million in Europe.

Gene Therapy

Gene Therapy Gene Gene Sequencing Gene Expression

Takeda grows in gene therapies again with $2bn Code Bio deal

Zynteglo halt re-ignites viral vector safety concerns; analysts

Stay Connected